Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Slides:

Advertisements

Similar presentations

Fig. 2. Comparison of the Th1/Th2 ratio and the percentages of Th1 and Th2 cells between normal and allergic individuals. (A) The Th1/Th2 ratio observed.

Advertisements

Synergistic antitumor effect of anti-CD40/CpG and 14

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Dose-escalation patient response.

Melanoma donor (MD) NK cells are functionally impaired/exhausted.

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Suppressive effect of CD39+CD73+ melanoma cells on T-cell proliferation, and reversion of this effect via treatment with the CD39-blocking antibody, CD39.

Low-dose cyclophosphamide (Cy) reduces intratumoral Treg numbers and promotes enhanced T-cell trafficking and activation within the tertiary lymphoid aggregates.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Figure 1 Effect of DMF therapy on T cell subsets

Tregs and APC subsets in TDLNs of patients with cervical cancer.

Supplemental Digital Content 2 – Figure 1

Postoperative changes in blood monocyte subsets.

Volume 17, Issue 2, Pages (February 2009)

Volume 19, Issue 7, Pages (July 2011)

mpJX-594 effects on tumor burden and leukocyte influx.

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

PTX in combination with PLX397 induces antitumor T-cell response.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

RvD1 increased anti-inflammatory macrophages and Treg cells in the sciatic nerves of EAN rats. RvD1 increased anti-inflammatory macrophages and Treg cells.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

Increased CCL5 expression, infiltration of Treg cells, and apoptosis of CD8+ T cells in human colorectal tissues. Increased CCL5 expression, infiltration.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

PD-L1 expression by melanocytes is observed in geographic association with TILs but does not depend on BRAF V600E. PD-L1 expression by melanocytes is observed.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

pDCs from the melanoma environment responded to TLR-L stimulation.

Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. A.

AXL is not expressed in human prostate tumors.

Presentations of thyroid disorders after receiving immune checkpoint inhibition combination therapy or monotherapy. Presentations of thyroid disorders.

Melanoma patient monocytes have altered expression of inflammatory and surface markers. Melanoma patient monocytes have altered expression of inflammatory.

Clinical benefit from combination limb infusion and CTLA-4 blockade.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

5FU-induced specific activation of CD8+ T cells.

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Canonical but not adaptive NK-cell function is suppressed by Tregs.

Abnormal monocyte distribution and loss of HLA-DR in patients with stage IV melanoma. Abnormal monocyte distribution and loss of HLA-DR in patients with.

PD-L1 is expressed in breast cancer.

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

CPI-444 enhances T-cell activation in MC38 tumors.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Immune profiling of patient-derived organotypic tumor spheroids.

Biopsies of the vaccination site were obtained 48 h after the first vaccination. Biopsies of the vaccination site were obtained 48 h after the first vaccination.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways. In situ expression of signature genes in the Th1, Th2, Th17, and Treg pathways.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Activation status of NK cells is associated with therapeutic effects of TKIs. PBMCs from CML patients were cocultured with HLA class I–deficient K562 cells.

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells. Coculture with U937 cells enhances DNMT1 expression in gastric cancer cells.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

MDSC population in patient peripheral blood.

Immunological effects of anticancer therapy.

EC-derived SP cells are targeted by CD30.CAR T cells.

RIL21 and checkpoint blockade restore IFNγ production in Tim-3+PD-1+ intratumoral NK cells from cancer patients. rIL21 and checkpoint blockade restore.

Trametinib and combination decrease T-lymphocyte proliferation.

Presentation transcript:

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. A patient with metastatic melanoma was treated with combined BRAF-targeted therapy plus CTLA4 blockade. A, timeline showing treatment schedule and biopsies; B, CD8+ T-cell infiltrate was determined by IHC (×40 magnification). C and D, immune cells isolated from tumors were analyzed by flow cytometry. C, CD3+ lymphocytes (top); populations of CD4+ and CD8+ lymphocytes pregated on CD3+ cells (middle); percentage of CD4+FoxP3+ Tregs and CD4+FoxP3− non-Tregs, pregated on CD3+CD4+ T cells (bottom). FSC-H, forward scatter height. The ratio of CD8+ T cells to CD4+FoxP3+ Treg cells is shown (C) and plotted versus time (D). Zachary A. Cooper et al. Cancer Immunol Res 2014;2:643-654 ©2014 by American Association for Cancer Research